Development of a regulatable oncolytic herpes simplex virus type 1 recombinant virus for tumor therapy

Journal of Virology

Volumn 84, Issue 16, 2010, Pages 8163-8171

  Yao, Feng ^a   Murakami, Nao ^a   Bleiziffer, Oliver ^a,b   Zhang, Pengwei ^a   Akhrameyeva, Natali V ^a   Xu, Ximing ^a   Brans, Richard ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; KTR 27; TETRACYCLINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER THERAPY; CYTOTOXICITY; DOWN REGULATION; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; VIROTHERAPY; VIRUS REPLICATION; VIRUS VIRULENCE;

ANIMALS; CELL LINE; CERCOPITHECUS AETHIOPS; DISEASE MODELS, ANIMAL; FEMALE; GENETIC ENGINEERING; GENETICS, MICROBIAL; HERPESVIRUS 1, HUMAN; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR BIOLOGY; ONCOLYTIC VIRUSES; RECOMBINATION, GENETIC;

HUMAN HERPESVIRUS 1; MUS MUSCULUS;

EID: 77954972681     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00059-10     Document Type: Article

References (54)

1. Advani, S. J., G. S. Sibley, P. Y. Song, D. E. Hallahan, Y. Kataoka, B. Roizman, and R. R. Weichselbaum. 1998. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors. Gene Ther. 5:160-165.
2. Aghi, M., and R. L. Martuza. 2005. Oncolytic viral therapies - the clinical experience. Oncogene 24:7802-7816. (Pubitemid 41670681)
3. Andreansky, S., B. He, J. van Cott, J. McGhee, J. M. Markert, G. Y. Gillespie, B. Roizman, and R. J. Whitley. 1998. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther. 5:121-130. (Pubitemid 28045078)
4. Augustinova, H., D. Hoeller, and F. Yao. 2004. The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice. J. Virol. 78: 5756-5765. (Pubitemid 38661663)
5. - viruses. J. Virol. 80:4528-4537.
6. Cai, W. Z., and P. A. Schaffer. 1989. Herpes simplex virus type 1 ICP0 plays a critical role in the de novo synthesis of infectious virus following transfection of viral DNA. J. Virol. 63:4579-4589.
7. Chambers, R., G. Y. Gillespie, L. Soroceanu, S. Andreansky, S. Chatterjee, J. Chou, B. Roizman, and R. J. Whitley. 1995. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a SCID mouse model of human malignant glioma. Proc. Natl. Acad. Sci. U. S. A. 92:1411-1415.
8. Chase, M., R. Y. Chung, and E. A. Chiocca. 1998. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat. Biotechnol. 16:444-448.
9. Chong, H., A. Ruchatz, T. Clackson, V. M. Rivera, and R. G. Vile. 2002. A system for small-molecule control of conditionally replication-competent adenoviral vectors. Mol. Ther. 5:195-203.
10. Chung, R. Y., Y. Saeki, and E. A. Chiocca. 1999. B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells. J. Virol. 73:7556-7564.
11. Currier, M. A., R. A. Gillespie, N. M. Sawtell, Y. Y. Mahller, G. Stroup, M. H. Collins, H. Kambara, E. A. Chiocca, and T. P. Cripe. 2008. Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide. Mol. Ther. 16:879-885.
12. Degenkolb, J., M. Takahashi, G. A. Ellestad, and W. Hillen. 1991. Structural requirements of tetracycline-Tet repressor interaction: determination of equilibrium binding constants for tetracycline analogs with the Tet repressor. Antimicrob. Agents Chemother. 35:1591-1595.
13. Eidson, K. M., W. E. Hobbs, B. J. Manning, P. Carlson, and N. A. DeLuca. 2002. Expression of herpes simplex virus ICP0 inhibits the induction of interferon-stimulated genes by viral infection. J. Virol. 76:2180-2191.
14. Everett, R. D. 2006. Interactions between DNA viruses, ND10 and the DNA damage response. Cell Microbiol. 8:365-374. (Pubitemid 43356028)
15. Fabbri, M., D. Iliopoulos, F. Trapasso, R. I. Aqeilan, A. Cimmino, N. Zanesi, S. Yendamuri, S. Y. Han, D. Amadori, K. Huebner, and C. M. Croce. 2005. WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 102:15611-15616.
16. Fechner, H., X. Wang, M. Srour, U. Siemetzki, H. Seltmann, A. P. Sutter, H. Scherubl, C. C. Zouboulis, R. Schwaab, W. Hillen, H. P. Schultheiss, and W. Poller. 2003. A novel tetracycline-controlled transactivator-transrepressor system enables external control of oncolytic adenovirus replication. Gene Ther. 10:1680-1690. (Pubitemid 37069496)
17. Hummel, J. L., E. Safroneeva, and K. L. Mossman. 2005. The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma. Mol. Ther. 12:1101-1110.
18. Kastan, M. B., and J. Bartek. 2004. Cell-cycle checkpoints and cancer. Nature 432:316-323.
19. Kasuya, H., T. M. Pawlik, J. T. Mullen, J. M. Donahue, H. Nakamura, S. Chandrasekhar, H. Kawasaki, E. Choi, and K. K. Tanabe. 2004. Selectivity of an oncolytic herpes simplex virus for cells expressing the DF3/MUC1 antigen. Cancer Res. 64:2561-2567. (Pubitemid 38523913)
20. Kramm, C. M., M. Chase, U. Herrlinger, A. Jacobs, P. A. Pechan, N. G. Rainov, M. Sena-Esteves, M. Aghi, F. H. Barnett, E. A. Chiocca, and X. O. Breakefield. 1997. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum. Gene Ther. 8:2057-2068.
21. Lee, C. Y., L. X. Bu, A. DeBenedetti, B. J. Williams, P. S. Rennie, and W. W. Jia. 2010. Transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1 for targeting prostate tumors. Mol. Ther. 18:929-935.
22. Leib, D. A., D. M. Coen, C. L. Bogard, K. A. Hicks, D. R. Yager, D. M. Knipe, K. L. Tyler, and P. A. Schaffer. 1989. Immediate-early regulatory gene mutants define different stages in the establishment and reactivation of herpes simplex virus latency. J. Virol. 63:759-768.
23. Liu, B. L., M. Robinson, Z. Q. Han, R. H. Branston, C. English, P. Reay, Y. McGrath, S. K. Thomas, M. Thornton, P. Bullock, C. A. Love, and R. S. Coffin. 2003. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 10:292-303.
24. Liu, T. C., and D. Kirn. 2008. Gene therapy progress and prospects cancer: oncolytic viruses. Gene Ther. 15:877-884. (Pubitemid 351791475)
25. Liu, T. C., and D. Kirn. 2007. Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. Cancer Res. 67:429-432.
26. Liu, T. C., T. Zhang, H. Fukuhara, T. Kuroda, T. Todo, R. L. Martuza, S. D. Rabkin, and A. Kurtz. 2006. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Mol. Ther. 14:789-797.
27. MacLean, A. R., and S. M. Brown. 1987. A herpes simplex virus type 1 variant which fails to synthesize immediate early polypeptide VmwIE63. J. Gen. Virol. 68:1339-1350.
28. Mahller, Y. Y., S. S. Vaikunth, M. C. Ripberger, W. H. Baird, Y. Saeki, J. A. Cancelas, T. M. Crombleholme, and T. P. Cripe. 2008. Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors. Cancer Res. 68:1170-1179.
29. Martuza, R. L., A. Malick, J. M. Markert, K. L. Ruffner, and D. M. Coen. 1991. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252:854-856.
30. McKee, T. D., P. Grandi, W. Mok, G. Alexandrakis, N. Insin, J. P. Zimmer, M. G. Bawendi, Y. Boucher, X. O. Breakefield, and R. K. Jain. 2006. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res. 66:2509-2513.
31. Mineta, T., S. D. Rabkin, T. Yazaki, W. D. Hunter, and R. L. Martuza. 1995. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. 1:938-943.
32. Miyatake, S., A. Iyer, R. L. Martuza, and S. D. Rabkin. 1997. Transcriptional targeting of herpes simplex virus for cell-specific replication. J. Virol. 71: 5124-5132. (Pubitemid 27258184)
33. Mohr, I. 2005. To replicate or not to replicate: achieving selective oncolytic virus replication in cancer cells through translational control. Oncogene 24:7697-7709. (Pubitemid 41670672)
34. Moses, M. A., H. Brem, and R. Langer. 2003. Advancing the field of drug delivery: taking aim at cancer. Cancer Cell 4:337-341.
35. Mossman, K. L., H. A. Saffran, and J. R. Smiley. 2000. Herpes simplex virus ICP0 mutants are hypersensitive to interferon. J. Virol. 74:2052-2056.
36. Mossman, K. L., and J. R. Smiley. 2002. Herpes simplex virus ICP0 and ICP34.5 counteract distinct interferon-induced barriers to virus replication. J. Virol. 76:1995-1998.
37. Mullen, J. T., H. Kasuya, S. S. Yoon, N. M. Carroll, T. M. Pawlik, S. Chandrasekhar, H. Nakamura, J. M. Donahue, and K. K. Tanabe. 2002. Regulation of herpes simplex virus 1 replication using tumor-associated promoters. Ann. Surg. 236:502-512.
38. Mundargi, R. C., S. Srirangarajan, S. A. Agnihotri, S. A. Patil, S. Ravindra, S. B. Setty, and T. M. Aminabhavi. 2007. Development and evaluation of novel biodegradable microspheres based on poly(D,L-lactide-co-glycolide) and poly(epsilon-caprolactone) for controlled delivery of doxycycline in the treatment of human periodontal pocket: in vitro and in vivo studies. J. Control Release 119:59-68.
39. Parato, K. A., D. Senger, P. A. Forsyth, and J. C. Bell. 2005. Recent progress in the battle between oncolytic viruses and tumours. Nat. Rev. Cancer 5:965-976.
40. Parker, J. N., G. Y. Gillespie, C. E. Love, S. Randall, R. J. Whitley, and J. M. Markert. 2000. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc. Natl. Acad. Sci. U. S. A. 97:2208-2213.
41. Roizman, B., and D. M. Knipe. 2001. Herpes simplex viruses and their replication, p. 2399-2459. In D. M. Knipe and P. M. Howley (ed.), Fields virology, 4th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
42. Sandri-Goldin, R. M. 2008. The many roles of the regulatory protein ICP27 during herpes simplex virus infection. Front Biosci. 13:5241-5256.
43. Sipo, I., X. Wang, A. Hurtado Pico, L. Suckau, S. Weger, W. Poller, and H. Fechner. 2006. Tamoxifen-regulated adenoviral E1A chimeras for the control of tumor selective oncolytic adenovirus replication in vitro and in vivo. Gene Ther. 13:173-186. (Pubitemid 43039909)
44. Spivack, J. G., and N. W. Fraser. 1988. Expression of herpes simplex virus type 1 (HSV-1) latency-associated transcripts and transcripts affected by the deletion in avirulent mutant HFEM: evidence for a new class of HSV-1 genes. J. Virol. 62:3281-3287.
45. Taneja, S., J. MacGregor, S. Markus, S. Ha, and I. Mohr. 2001. Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells. Proc. Natl. Acad. Sci. U. S. A. 98:8804-8808.
46. Todo, T., R. L. Martuza, M. J. Dallman, and S. D. Rabkin. 2001. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity. Cancer Res. 61:153-161.
47. Walsh, D., and I. Mohr. 2004. Phosphorylation of eIF4E by Mnk-1 enhances HSV-1 translation and replication in quiescent cells. Genes Dev. 18:660-672. (Pubitemid 38489934)
48. Wong, R. J., S. G. Patel, S. Kim, R. P. DeMatteo, S. Malhotra, J. J. Bennett, M. St-Louis, J. P. Shah, P. A. Johnson, and Y. Fong. 2001. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum. Gene Ther. 12:253-265.
49. Yao, F., and E. Eriksson. 1999. A novel anti-herpes simplex virus type 1-specific herpes simplex virus type 1 recombinant. Hum. Gene Ther. 10: 1811-1818.
50. Yao, F., and P. A. Schaffer. 1995. An activity specified by the osteosarcoma line U2OS can substitute functionally for ICP0, a major regulatory protein of herpes simplex virus type 1. J. Virol. 69:6249-6258.
51. Yao, F., T. Svensjo, T. Winkler, M. Lu, C. Eriksson, and E. Eriksson. 1998. Tetracycline repressor, tetR, rather than the tetR-mammalian cell transcription factor fusion derivatives, regulates inducible gene expression in mammalian cells. Hum. Gene Ther. 9:1939-1950.
52. Yao, F., C. Theopold, D. Hoeller, O. Bleiziffer, and Z. Lu. 2006. Highly efficient regulation of gene expression by tetracycline in a replication-defective herpes simplex viral vector. Mol. Ther. 13:1133-1141.
53. Yen, L., J. Svendsen, J. S. Lee, J. T. Gray, M. Magnier, T. Baba, R. J. D'Amato, and R. C. Mulligan. 2004. Exogenous control of mammalian gene expression through modulation of RNA self-cleavage. Nature 431:471-476. (Pubitemid 39329588)
54. Zhang, H., K. Takayama, L. Zhang, J. Uchino, A. Harada, T. Harada, J. Hisasue, N. Nakagaki, C. Zhou, and Y. Nakanishi. 2009. Tetracycline-inducible promoter-based conditionally replicative adenoviruses for the control of viral replication. Cancer Gene Ther. 16:415-422.